Evofem Biosciences (EVFM) Q4 2025 earnings summary

Executive summary

• Achieved record net sales of $20.2 million in 2025, marking the fifth consecutive year of net sales growth, primarily driven by PHEXX and SOLOSEC sales.

• Income from operations rose to $3.4 million in 2025, compared to a loss of $7.7 million in 2024.

• Net income attributable to common stockholders was $0.3 million in 2025, versus a net loss of $9.0 million in 2024.

Financial highlights

• Net sales increased 4% year-over-year to $20.2 million in 2025, up from $19.4 million in 2024.

• Fourth quarter 2025 net sales were $9.6 million, a 35% increase from $7.1 million in Q4 2024.

• Total operating expenses dropped 38% to $16.8 million in 2025, driven by reductions in R&D and G&A expenses.

• Operating income for Q4 2025 was $3.3 million, compared to a $1.0 million loss in Q4 2024.

• Q4 2025 net income was $2.8 million, versus a net loss of $3.0 million in Q4 2024.

Outlook and guidance

• Initiatives underway to lower manufacturing costs for both PHEXX and SOLOSEC, targeting 55-60% reductions.

• Anticipated regulatory approval for PHEXX in the UAE following favorable pricing certificates.

• EDE review of SOLOSEC application in the UAE is ongoing.